Showing results (511-520 of 555) with videos related to

Sort By:
Pageof 56
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
The Journal of Clinical Investigation|October 4, 2022
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A Sena, Rajendra Kumar, David E Sanin, et al.
Nature Cancer|June 4, 2021
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistanceJuan M Arriaga, Sukanya Panja, Mohammed Alshalalfa, et al.
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic EssentialityAli T Arafa, Siddhartha Yadav, Catherine H Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical OutcomesJustin Hwang, Xiaolei Shi, Andrew Elliott, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancerRebeca Lozano, Daniela C Salles, Shahneen Sandhu, et al.
Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.
European Urology|May 13, 2026
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate CancerLuka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al.
JAMA Oncology|March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical TrialRyan Phillips, William Yue Shi, Matthew Deek, et al.
Pageof 56